es with a market-leading multifocal lens. Among patients with ADDs of +1.25 to +2.50, Proclear 1 day multifocal lenses scored equivalent for near vision and equivalent or better for intermediate and distance vision after one hour of wear. In the same study, Proclear 1 day multifocal lenses were preferred for vision among patients with ADDs of +2.00 to +2.50 after one hour of wear.
Convenience and Health
With daily disposable lenses, the cost and hassle of a lens care solution is eliminated. And because the lenses are replaced each day, they are one of the healthiest modalities available. Proclear 1 day multifocal lenses provide patients with the freedom to maintain an active and social lifestyle, allowing the wearer to decide whether to wear the lenses all day, part of the day, or reserve them for special situations. Plus, as your prescription changes, your eye care practitioner can easily adjust it, which means minimal disturbance to your vision, shorter appointments, and fewer follow-ups.
"With Proclear 1 day multifocal lenses, people get fresh lenses every day," added Murphy."For many, this also represents a fresh start to their contact wearing experience."
CooperVision offers a broad portfolio of multifocal lenses on the market. The latest lens, Proclear 1 day multifocal, is manufactured with the company's PC Technology™, a unique lens material that attracts and maintains moisture, thus reducing dryness.
The lens will be launched initially in the U.S., Canada, Australia, New Zealand, and a number of European countries. For more information on CooperVision's comprehensive line of multifocal contact lenses, visit www.coopervision.com/multifocal.
About CooperVision
CooperVision, a unit of The Cooper Companies, Inc. (NYSE: COO), is one of the world'
'/>"/>
SOURCE CooperVision Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients2.
OncoSec Medical Featured in Medical Device Daily3.
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD4.
Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin5.
Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome6.
PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry7.
Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections8.
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration9.
Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures10.
Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union11.
BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan